<!DOCTYPE html>
<html>

<head>
    <title>RWD Wall</title>
    <link rel="stylesheet" type="text/css" media="screen" href="css/styles.css" />
    <script src="js/jquery.min.js"></script>
    <script src="js/jquery.slides.js"></script>
    <!--<script src="js/attrchange.js"></script>-->
    <script src="/socket.io/socket.io.js"></script>
    <script src="js/receiver.js"></script>
</head>

<body>
    <section id="Container" class=""> <!--insert Phase_2 class here-->
        <!--Slideshow container-->
        <div id="slides_container" class="">
            <div class="slides">
                <img src="images/Profile_1.jpg" alt="" class="Profile_1 current">
                <img src="images/Profile_2.jpg" alt="" class="Profile_2">
                <img src="images/Profile_3.jpg" alt="" class="Profile_3">
                <img src="images/Profile_4.jpg" alt="" class="Profile_4"> 
            </div>
        </div>
       
        <!--video section: both 'screensaver' and transition profile videos load here-->
        <div id="video_container" class="">
            <video class="Profile" id="Profile_1">
                <source src="video/Profile_1.mp4" type="video/mp4">
            </video>
            <video class="Profile" id="Profile_2">
                <source src="video/Profile_2.mp4" type="video/mp4">
            </video>
            <video class="Profile" id="Profile_3">
                <source src="video/Profile_3.mp4" type="video/mp4">
            </video>
            <video class="Profile" id="Profile_4">
                <source src="video/Profile_4.mp4" type="video/mp4">
            </video>
        </div>

        <!--header is used for heading titles-->
        <header>
            <h2 class="preheader">From clinical trials to clinical practice:</h2>
            <h1>bring real-world data to life</h1>
        </header>

        <section id="Bio"></section>
        
        <nav id="Patients">
            <ul>
                <li class="Profile_1"></li>
                <li class="Profile_2"></li>
                <li class="Profile_3"></li>
                <li class="Profile_4"></li>
            </ul>
        </nav>
       
        <!--Profile 1 sections-->
        <section id="Testimonial" class="Profile_1">
            <ul>
                <li>
                    “I’m cured! I couldn’t believe it when 
                    I got the results. My liver is still pretty 
                    healthy, so now the future looks bright 
                    for me and the children”
                </li>
                <li>
                    “My treatment was quite simple – 
                    just one pill each morning while the 
                    children had their breakfast.”
                </li>
                <li>
                    “My treatment was quite simple – 
                    just one pill each morning while the 
                    children had their breakfast.”
                </li>
            </ul>
        </section>
        
        <section id="Keypoints" class="Profile_1">
            <ul>
                <li>
                    Up to <strong>100% cure</strong> in real-world 
                    HCV GT1 treatment-naïve patients 
                    without cirrhosis treated with 8-week 
                    HARVONI (n=543)<sup>1–4,a,b</sup>
                    <button class="P1_popup_1"></button>
                    <div class="P1_popup_1">
                        <img src="/images/Profile_1_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    HARVONI offers a single-tablet 
                    regimen for the majority of HCV GT1 
                    patients.<sup>5,c</sup> <strong>96% treatment adherence</strong> 
                    was observed in real-world patients 
                    treated with 8-week HARVONI3,<sup>d</sup>
                    <button class="P1_popup_2"></button>
                    <div class="P1_popup_2">
                        <img src="/images/Profile_1_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    Up to <strong>100% completion</strong> rates were 
                    seen in real-world patients treated 
                    with 8-week HARVONI<sup>1–4</sup>
                    <button class="P1_popup_3"></button>
                    <div class="P1_popup_3">
                        <img src="/images/Profile_1_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
            </ul>
        </section>
       
        <!--Profile 2 sections-->
        <section id="Testimonial" class="Profile_2">
            <ul>
                <li>
                    “There’s a lot of stigma around having HCV, especially being coinfected. But now I’m cured, I don’t have to worry about it.”
                </li>
                <li>
                    “I didn’t even have to change my HIV medication – that was such a relief.”
                </li>
                <li>
                    “My job is important and I can’t afford to take time off. With this treatment, I didn’t have to.”
                </li>
            </ul>
        </section>

        <section id="Keypoints" class="Profile_2">
            <ul>
                <li>
                    Up to <strong>100% cure</strong> in eligible real-world HIV/HCV-coinfected patients treated with HARVONI for 8 weeks<sup>1–4,a,b</sup>
                    <button class="P2_popup_1"></button>
                    <div class="P2_popup_1">
                        <img src="/images/Profile_1_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    HARVONI can be coadministered with all classes of HIV antiviral agents<sup>2,c</sup>
                    was observed in real-world patients 
                    treated with 8-week HARVONI3,<sup>d</sup>
                    <button class="P2_popup_2"></button>
                    <div class="P2_popup_2">
                        <img src="/images/Profile_1_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    HARVONI is <strong>well tolerated</strong> up to 100% of real-world patients completed 8-week therapy with HARVONI<sup>1,3,4,d</sup>
                    <button class="P2_popup_3"></button>
                    <div class="P2_popup_3">
                        <img src="/images/Profile_1_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
            </ul>
        </section>
       
       
       
        <!--Footer used for main footnotes-->
        <footer>
           <!--TODO: format footer here-->
            <p><sup>a</sup> Treatment-naïve HCV GT1 patients without cirrhosis may be considered for 8-week treatment with HARVONI.5<br>
            <sup>b</sup> EASL defines cure as SVR12.6<br>
            <sup>c</sup> 2% (31/1648) discontinued treatment early. This includes patients treated with 8, 12, 24 and other weeks of HARVONI ± RBV.1<br>
             <sup>d</sup> Evidence of non-adherence was assessed upon the discretion of the investigators, and based on patient adherence to schedules and appointments, patient statements and congruence to the prescriptions.3</p>
            
            <ol>
                <li>Terrault N et al. Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study. Oral 94 presented at the Liver Meeting 2015, San Francisco, CA, USA 2015. Available from http://www.natap.org/2015/AASLD/AASLD_04.htm. Accessed January 2016.</li>
                
                <li>Curry MP et al. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. Poster 1046 presented at the Liver Meeting 2015, San Francisco, CA, USA 2015. Available from http://triohealth.com/wp-content/uploads/2015/11/Poster-Study-1-Final.pdf. Accessed January 2016.</li>
                
                <li>Buggisch P et al. Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment. Poster 1205 presented at the Liver Meeting 2015, San Francisco, CA, USA 2015. Available from http://www.aasld.org/sites/default/files/2015SupplementFULLTEXT.pdf. Accessed January 2016.</li>
                
                <li>Christensen S et al. Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice – Results from the German hepatitis C Cohort (GECCO).Poster 1081 presented at the Liver Meeting 2015, San Francisco, CA, USA 2015. Available from http://www.aasld.org/sites/default/files/2015SupplementFULLTEXT.pdf. Accessed January 2016.</li>
                <li>HARVONI Summary of Product Characteristics, January 2016. 6. European Association for the Study of the Liver (EASL). Recommendations on Treatment of Hepatitis C. J Hepatol 2015;63:199–236.</li>
            </ol>
        </footer>
        
        
        <div id="BG_source">
            <video autoplay loop>
                <source src="video/Profile_1_BG.mp4" type="video/mp4">
            </video>
        </div>
    </section>

    <div id="IdleModal">
        <p>You have been inactive for a while, close the window to continue or the app will reset in:</p>
        <span class="countdown">20</span>
        <div class="close_btn"></div>
    </div>


</body>

</html>